Ataxia
42
9
9
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.8%
2 terminated out of 42 trials
91.7%
+5.2% vs benchmark
2%
1 trials in Phase 3/4
5%
1 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (42)
"Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis"
RFC1 Natural History Study
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
Effects of Cerebellar tACS-iTBS in Ataxia
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Can Acute Photobiomodulation Improve Balance and Cognition in Individuals With Ataxia: a Pilot Feasibility Placebo Randomized Controlled Trial.
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Home-based Gait and Balance Training in Patients With Movement Disorders
Structural Validity and Inter-rater Reliabitiliy of the Ataxia Trunk, Lower And Upper Extremity Scale (ATLAS)
Neuroimmunology Registry and Biobank
Home Exercise for Individuals with Neurodegenerative Disease
Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises
Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy
Validation of Bulbicam for Parkinson- and Ataxia-patients
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
Teleassessment in Ataxic Multiple Sclerosis
Rehabilitation Program on Genetic and Degenerative Ataxia
PatientSpot Formerly Known as ArthritisPower
Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients
Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders